Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

Optimisation of Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

The study aims to evaluate the biochemical and clinical effectiveness on symptoms and tumor size of a monotherapy with Lanreotide 120mg in acromegalic subjects, to describe criteria for starting alternative strategies, and to describe the modalities and the global effectiveness of alternative strategies.

Inclusion Criteria:

• Male or female aged 18 years or more, suffering from acromegaly
• Treatment naïve or treated subject (whatever the previous treatments except Lanreotide 120mg and radiotherapy) who does not achieve biochemical control in the physician's opinion. Requiring a treatment with Somatostatin analog (SSA)
• Having performed a Magnetic Resonance Imaging (MRI) to evaluate the tumor size within the previous 12 weeks (post-surgery MRI for operated subjects)
• In whom the physician has already decided to initiate a treatment with Lanreotide 120mg as a monotherapy

Exclusion Criteria:

• Subject previously/currently treated with Lanreotide 120mg
• History of radiotherapy for acromegaly
• Subject who requires a surgical intervention for relief of any sign or symptom associated with tumor compression
• Concomitant prolactin hypersecretion requiring a treatment with dopaminergic agonists
• Active neoplastic disease